Human Tumor Sequencing Project (HuTS)
This study has been completed.
Information provided by (Responsible Party):
Eric Topol, MD, Scripps Translational Science Institute
First received: May 25, 2012
Last updated: November 17, 2014
Last verified: November 2014
This study is being done to learn more about genetic mutations in cancer cells and to find out how the development of new technologies can increase knowledge of these mutations and possibly predict an individual's response to certain treatments.
||Observational Model: Case-Only
Time Perspective: Prospective
||Human Tumor Sequencing Project
Primary Outcome Measures:
- Determine biomarkers of clinical utility and copy number variants through genetic analysis. [ Time Frame: four years ] [ Designated as safety issue: No ]
| Study Start Date:
| Study Completion Date:
| Primary Completion Date:
||April 2014 (Final data collection date for primary outcome measure)
|Ages Eligible for Study:
||18 Years and older
|Genders Eligible for Study:
|Accepts Healthy Volunteers:
- Diagnosis of a solid tumor or blood borne cancer
- 18 years or older
- Eligible to have blood drawn
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01608230
|Scripps Translational Science Institute
|La Jolla, California, United States, 92037 |
Scripps Translational Science Institute
No publications provided
ClinicalTrials.gov processed this record on May 05, 2015
||Eric Topol, MD, Director, Scripps Translational Science Institute
History of Changes
|Other Study ID Numbers:
|Study First Received:
||May 25, 2012
||November 17, 2014
||United States: Institutional Review Board